News Search Results
Oct 27, 2025, 10:30 ET Electronic Trial Master File (eTMF) Systems Market worth $2.49 billion by 2030 with 12.8% CAGR | MarketsandMarkets™
systems across the pharmaceutical and biotechnology sectors. By geography, North America dominated the electronic trial master file (eTMF) systems market in 2024, driven by a strong presence of pharmaceutical and biotechnology companies, advanced clinical research
More news about: MarketsandMarkets
Oct 27, 2025, 10:20 ET Chromatin Bioscience Announces Collaboration with Purespring Therapeutics
across the gene therapy landscape. About Chromatin BioscienceChromatin Bioscience is a biotechnology company focused on the design and development of synthetic promoters for targeted eukaryotic gene control systems. Its proprietary platform, chromatinLENS
More news about: CHROMATIN BIOSCIENCE LTD
Oct 27, 2025, 10:15 ET Chromatin Bioscience Announces Collaboration with Purespring Therapeutics
across the gene therapy landscape. About Chromatin BioscienceChromatin Bioscience is a biotechnology company focused on the design and development of synthetic promoters for targeted eukaryotic gene control systems. Its proprietary platform, chromatinLENS
More news about: CHROMATIN BIOSCIENCE LTD
Oct 27, 2025, 09:01 ET Granata Bio Corporation and Georgetown Equity Partners Announce Joint Venture to Develop a Novel, Next-Generation Form of Follicle-Stimulating Hormone (FSH)
BOSTON and DENVER, Oct. 27, 2025 /PRNewswire/ -- Granata Bio Corporation, a biotechnology company dedicated to advancing fertility and reproductive health, and Georgetown Equity Partners (GEP) today announced the formation of a joint
More news about: Granata Bio
Oct 27, 2025, 09:00 ET Trinity Consultants Unites Life Sciences Brands
"As the pharmaceutical, biotechnology and health care industries are evolving with increased velocity, one unified brand allows us to bring the full range of our expertise to every client;
More news about: Trinity Consultants
Oct 27, 2025, 08:31 ET MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting
CAMBRIDGE, Mass., Oct. 27, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data on Vanoglipel (DA-1241), a novel G-Protein-Coupled
More news about: MetaVia Inc.
Oct 27, 2025, 08:30 ET BioDlink Completes First International Shipment of Bevacizumab to Colombia
therapeutic fields, builds cutting-edge biotechnology platforms such as new protein, new antibody, nucleic acid drugs, and adheres to the platform driven development model of "innovation+internationalization", At the same time, it explores the extensive application of biotechnology in the field of general health,
More news about: BioDlink Biopharm Co., Ltd.
Oct 27, 2025, 08:30 ET Advancing Cell Therapy Development with Integrated Analytical and Process Strategies, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 27, 2025, 08:30 ET Every Patient Matters: Bespoke Digital Endpoint Strategies for Rare Disease Drug Development, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 27, 2025, 08:16 ET MOONLAKE IMMUNOTHERAPEUTICS SECURITIES FRAUD NOTICE: Berger Montague Informs MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors of Securities Fraud Lawsuit
CLICK HERE. MoonLake is a clinical-stage biotechnology company headquartered in Zug, Switzerland. According to the lawsuit, MoonLake and certain executives made
More news about: Berger Montague
Oct 27, 2025, 08:05 ET INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025
PLYMOUTH MEETING, Pa., Oct. 27, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Oct 27, 2025, 08:00 ET Pancreatic Cancer Clinical Trial Data for Diakonos Oncology's DOC1021 Cell-Based Immunotherapy to be Presented at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced a poster presentation at the
More news about: Diakonos Oncology
Oct 27, 2025, 07:40 ET MLTX INVESTOR NOTICE: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
later than December 15, 2025. CASE ALLEGATIONS: MoonLake is a clinical stage biotechnology company that focuses on developing therapies for inflammatory skin and joint diseases. According to the complaint, MoonLake's sole drug candidate
More news about: Robbins Geller Rudman & Dowd LLP
Oct 27, 2025, 07:15 ET ADC Therapeutics to Present at November Investor Conferences
Stephens Biotechnology Virtual Fireside Chats 2025Date: November 3, 2025Presentation Time: 12:00 p.m. ETFormat: Fireside ChatSpeaker:
More news about: ADC Therapeutics SA
Oct 27, 2025, 07:00 ET NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies
disorders and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), a clinical-stage biotechnology company developing breakthrough cell therapy solutions for severe diseases such as ALS and diabetes, today announced the signing of a Memorandum
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Oct 27, 2025, 07:00 ET Nanoscope Therapeutics President and Chief Scientific Officer Dr. Samarendra Mohanty to Be Featured Speaker at 2025 ISPE Annual Meeting and Expo
Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment
More news about: Nanoscope Therapeutics
Oct 27, 2025, 06:45 ET Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Oct 27, 2025, 06:00 ET Hemab Therapeutics Announces $157 Million Series C Financing to Advance Next-Generation Treatments for Underserved Bleeding Disorders
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Oct. 27, 2025 /PRNewswire/ -- Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the completion of
More news about: Hemab Therapeutics
Oct 27, 2025, 06:00 ET IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events
Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Maury Raycroft, Ph.D. Equity Research Analyst, Biotechnology A live audio webcast of the conference events, as permitted by the conference host, will be available
More news about: IDEAYA Biosciences, Inc.
Oct 27, 2025, 06:00 ET Ascletis to Present Study Results of ASC30 Oral Tablet, ASC30 Injection, and Combination of ASC31 and ASC47 at ObesityWeek® 2025
About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Oct 27, 2025, 01:00 ET EU Climate Ambitions at Risk Flawed Regulatory Framework Threatens Shipping Innovation
greater involvement of all stakeholders. About I-Tech AB I-Tech is a biotechnology company that has developed the antifouling technology Selektope®, an active substance that prevents barnacle attachment on submerged surfaces such
More news about: I-Tech
Oct 27, 2025, 01:00 ET EU Climate Ambitions at Risk Flawed Regulatory Framework Threatens Shipping Innovation
greater involvement of all stakeholders. About I-Tech AB I-Tech is a biotechnology company that has developed the antifouling technology Selektope®, an active substance that prevents barnacle attachment on submerged surfaces such
More news about: I-Tech
Oct 26, 2025, 23:20 ET CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit
More news about: CSL
Oct 26, 2025, 22:30 ET CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit
More news about: CSL
Oct 26, 2025, 07:42 ET STARS OF SCIENCE CROWNS SEASON 17 WINNER
levels and helps users take preventive action before mental health symptoms arise. Dardabou's invention impressed judges for its potential to blend biotechnology with emotional well-being, addressing a global challenge through accessible, everyday technology. Upon being named the winner,
More news about: Stars of Science